Clement Opoku-Temeng
Overview
Explore the profile of Clement Opoku-Temeng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Opoku-Temeng C, Dayal N, Hernandez D, Naganna N, Sintim H
Chem Commun (Camb)
. 2018 Apr;
54(36):4521-4524.
PMID: 29629444
Cyclin-dependent kinases have emerged as important targets for cancer therapy. HSD992, containing a novel scaffold based on the tetrahydro-3H-pyrazolo[4,3-a]phenanthridine core, inhibits CDK2/3 but not other CDKs and also potently inhibits...
12.
Larocque E, Naganna N, Opoku-Temeng C, Lambrecht A, Sintim H
ChemMedChem
. 2018 Apr;
13(12):1172-1180.
PMID: 29608815
The introduction of imatinib into the clinical scene revolutionized the treatment of chronic myelogenous leukemia (CML). The overall eight-year survival rate for CML has increased from about 6 % in...
13.
Wang M, Sooreshjani M, Mikek C, Opoku-Temeng C, Sintim H
Future Med Chem
. 2018 Mar;
10(11):1301-1317.
PMID: 29558821
Aim: Persistent activation of STING pathway is the basis for several autoimmune diseases. STING is activated by cGAMP, which is produced by cGAS in the presence of DNA. Results/methodology: HPLC-based...
14.
Dayal N, Opoku-Temeng C, Hernandez D, Sooreshjani M, Carter-Cooper B, Lapidus R, et al.
Future Med Chem
. 2018 Feb;
10(7):823-835.
PMID: 29437468
Aim: Approximately 30% of acute myeloid leukemia (AML) patients carry FLT3 tyrosine kinase domain (TKD) mutations or internal tandem duplication (FLT3-ITD). Currently there is a paucity of compounds that are...
15.
Opoku-Temeng C, Sintim H
Methods Mol Biol
. 2017 Sep;
1657:419-430.
PMID: 28889311
Bacteria possess several signaling molecules that regulate distinct phenotypes. Cyclic di-GMP (c-di-GMP) has emerged as a ubiquitous second messenger that regulates bacterial virulence, cell cycle, motility, and biofilm formation. The...
16.
Zhou J, Opoku-Temeng C, Sintim H
Methods Mol Biol
. 2017 Sep;
1657:245-261.
PMID: 28889299
c-di-GMP is widely recognized as an important ubiquitous signaling molecule in bacteria. c-di-GMP phosphodiesterases (PDEs) regulate the intracellular concentration of c-di-GMP and some could be potential drug targets. Here, we...
17.
Larocque E, Naganna N, Ma X, Opoku-Temeng C, Carter-Cooper B, Chopra G, et al.
Future Med Chem
. 2017 May;
9(11):1213-1225.
PMID: 28490193
Aim: Mutated or overexpressed FLT3 drives about 30% of reported acute myeloid leukemia (AML). Currently, FLT3 inhibitors have shown durable clinical responses but a complete remission of AML with FLT3...
18.
Opoku-Temeng C, Zhou J, Zheng Y, Su J, Sintim H
Chem Commun (Camb)
. 2016 Jun;
52(60):9327-42.
PMID: 27339003
Bacteria utilize nucleotide-based second messengers to regulate a myriad of physiological processes. Cyclic dinucleotides have emerged as central regulators of bacterial physiology, controlling processes ranging from cell wall homeostasis to...
19.
Opoku-Temeng C, Sintim H
Sci Rep
. 2016 May;
6:25445.
PMID: 27150552
Cyclic di-AMP has emerged as an important signaling molecule that controls a myriad of functions, including cell wall homeostasis in different bacteria. Polyphenols display various biological activities and tea polyphenols...
20.
Opoku-Temeng C, Sintim H
Chem Commun (Camb)
. 2016 Jan;
52(19):3754-7.
PMID: 26824279
C-di-AMP synthases are essential in several bacteria, including human pathogens; hence these enzymes are potential antibiotic targets. However, there is a dearth of small molecule inhibitors of c-di-AMP metabolism enzymes....